Interacting Drugs |
Rilonacept vs Canakinumab |
Security Level |
 |
Mechanism |
Canakinumab: Interleukin-1 Inhibitors may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear. |
Management |
Avoid combination |
Rilonacept vs Canakinumab
Post Review about Rilonacept vs Canakinumab Click here to cancel reply.
Other Interactions of Rilonacept
Other Interactions of Canakinumab
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.